The validation from a top-tier pharma partner and completion of an end-to-end AI platform significantly de-risks BullFrog AI’s technology proposition. Traders should monitor for follow-on deals, expansion of the current partnership, or additional monetization of bfPREP™ or bfARENAS™ modules as near-term catalysts. The extended runway reduces near-term dilution risk.
Price Chart
Executive Summary
BullFrog AI announced a commercial feasibility agreement with a top 5 global pharmaceutical company to identify drug targets in major depressive disorder using its bfLEAP® platform, supported by a proprietary dataset from Johns Hopkins and the Lieber Institute. The company also confirmed it has secured sufficient equity to meet Nasdaq listing standards and extended its financial runway into late 2027 through recent financing.
Key Facts
- Announced first commercial agreement with a top 5 global pharmaceutical company on March 30, 2026, focused on major depressive disorder (MDD), a market projected to exceed $11 billion by 2032.
- Agreement includes milestone payments and an option for the partner to secure exclusive rights to a final target candidate.
- Platform leverages over 2,800 human brain samples from collaboration with Johns Hopkins APL and the Lieber Institute for Brain Development.
- Recent financing activities have secured stockholders’ equity in excess of $2.5 million, meeting Nasdaq’s minimum equity requirement, with cash runway expected into late 2027.
- Launched bfARENAS™ in March 2026, completing what the company claims is the only fully integrated end-to-end AI platform purpose-built for pharmaceutical R&D.
Financial Impact
Milestone payments from agreement; no total deal value disclosed. Financing secured equity >$2.5M and operational runway into late 2027.
Risk Factors
- Company remains pre-revenue beyond milestone payments; future funding needs could lead to dilution.
- Forward-looking statements are speculative and dependent on successful execution and adoption by partners.
- Market cap of $16M suggests high volatility and sensitivity to sentiment, with limited liquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272396 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 20, 2026 9w ago | 8-K | $0.5500 $0.4638 | ▲ +15.67% | ▲ +15.67% | $0.4788 (+12.95%) |
Jun 15, 2026 19w ago | 8-K | $0.6934 $0.6927 | ▼ −0.10% | ▼ −0.30% | $0.4788 (−30.95%) |
Jun 11, 2026 19w ago | EFFECT | $0.6281 $0.7370 | ▼ −17.34% | ▼ −15.45% | $0.4788 (+23.77%) |
Apr 13, 2026 28w ago | Press Release | $1.05 $0.6570 | ▼ −37.43% | ▼ −45.16% | $0.4788 (−54.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers